Literature DB >> 11195772

Adult rhinosinusitis: diagnosis and management.

J D Osguthorpe1.   

Abstract

Rhinosinusitis can be divided among four subtypes: acute, recurrent acute, subacute and chronic, based on patient history and a limited physical examination. In most instances, therapy is initiated based on this classification. Antibiotic therapy, supplemented by hydration and decongestants, is indicated for seven to 14 days in patients with acute, recurrent acute or subacute bacterial rhinosinusitis. For patients with chronic disease, the same treatment regimen is indicated for an additional four weeks or more, and a nasal steroid may also be prescribed if inhalant allergies are known or suspected. Nasal endoscopy and computed tomography of the sinuses are reserved for circumstances that include a failure to respond to therapy as expected, spread of infection outside the sinuses, a question of diagnosis and when surgery is being considered. Laboratory tests are infrequently necessary and are reserved for patients with suspected allergies, cystic fibrosis, immune deficiencies, mucociliary disorders and similar disease states. Findings on endoscopically guided microswab culture obtained from the middle meatus correlate 80 to 85 percent of the time with results from the more painful antral puncture technique and is performed in patients who fail to respond to the initial antibiotic selection. Surgery is indicated for extranasal spread of infection, evidence of mucocele or pyocele, fungal sinusitis or obstructive nasal polyposis, and is often performed in patients with recurrent or persistent infection not resolved by drug therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11195772

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  24 in total

1.  [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; K Hörmann
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

Review 2.  Canadian guidelines for acute bacterial rhinosinusitis: clinical summary.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

3.  Nasal obstruction: a common presentation in primary care.

Authors:  Salma Mohamed; Noel Emmanuel; Neil Foden
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

4.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

5.  Bacterial biofilm in upper respiratory tract infections.

Authors:  David P Morris
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

6.  Effect of topical ofloxacin on bacterial biofilms in refractory post-sinus surgery rhino-sinusitis.

Authors:  W F Ezzat; S A Fawaz; H Rabie; T A Hamdy; Y A Shokry
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-29       Impact factor: 2.503

Review 7.  Short-course antimicrobial therapy of respiratory tract infections.

Authors:  David Guay
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Rhinitis in the geriatric population.

Authors:  Jayant M Pinto; Seema Jeswani
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-13       Impact factor: 3.406

Review 9.  Therapeutic targets in rhinosinusitis: infection or inflammation?

Authors:  Valerie J Lund
Journal:  Medscape J Med       Date:  2008-04-29

10.  Computed tomographic pulmonary changes in patients with chronic rhinosinusitis.

Authors:  Bruno Hochhegger; Giordano R T Alves; Klaus L Irion; Guilherme Watte; Betina Scheeren; Robson Rottenfuser; Edson Marchiori
Journal:  Br J Radiol       Date:  2015-08-06       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.